We report a severe case of *Chromobacterium haemolyticum* pneumonia associated with near-drowning and detail the investigation of the pathogen and river water. Our genomic and environmental investigation demonstrated that river water in a temperate region can be a source of *C. haemolyticum* causing human infections.

*Chromobacterium* is a genus of gram-negative, facultative anaerobic bacteria; application of 16S rRNA gene sequencing into bacterial taxonomy is expanding its species (1–5). Most *Chromobacterium* infections in humans have been caused by *C. violaceum* (6). Recently, exceptionally rare cases of *C. haemolyticum* infections have been described (2,4–7–9), but environmental sources of this pathogen have not been well investigated. We describe a case of *Chromobacterium*-associated pneumonia due to near-drowning and environmental investigation of a river site of the near-drowning. We used whole-genome sequencing (WGS) to identify the *Chromobacterium* species causing pneumonia associated with near-drowning and investigate molecular features, including antimicrobial resistance, virulence, and genetic relatedness of clinical and environmental isolates of *C. haemolyticum*.

**The Study**

This study was approved by the institutional review board of Tohoku University Graduate School of Medicine (IRB no. 2018-1-716). In June 2018, a man in his 70s was transported to our emergency center. He had altered consciousness and hypothermia at admission. He had fallen down a bank and into a river in the Tohoku region of Japan while intoxicated from alcohol and was found immersed in the river. He had respiratory failure and required intubation and mechanical ventilation. He had multiple fractures and a cervical cord injury. He had a history of hypertension, diabetes, and benign prostatic hyperplasia but was not immunodeficient. We diagnosed severe aspiration pneumonia and sepsis and treated the patient empirically with intravenous meropenem plus levofloxacin. We detected a nonpigmented, β-hemolytic gram-negative bacillus from both sputum and blood cultures. *C. violaceum* was identified by a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (VITEK MS; bioMérieux, https://www.biomerieux.com) with a confidence value of 99.9%. We changed the antimicrobial drug regimen to intravenous ceftazidime plus levofloxacin based on antimicrobial susceptibility testing pattern (Appendix 1 Table, https://wwwnc.cdc.gov/EID/article/26/9/19-0670-App1.pdf). After 3 weeks of intravenous therapy and critical care, the patient showed clinical improvement and had negative blood and sputum cultures. He was transferred to a community hospital for further rehabilitation and completed an additional 2 months of oral levofloxacin.

In mid-August, we conducted an environmental investigation of the river water in the area where the patient was found. We collected 500 mL samples of river water, 2 samples at the site where the patient was found and 1 sample 4 km upstream, where he likely fell into the river. We filtered samples through a
polyethersulfone filter membrane with a pore size of 0.22 μm. We placed the membrane filters on sheep blood agar plates and incubated for 24 hours at 35°C. We recovered a nonpigmented, β-hemolytic colony similar to clinical isolates from each of the cultures, which we identified as *C. violaceum*. We performed antimicrobial susceptibility testing by using a MicroScan WalkAway 96 plus (Beckman Coulter, https://www.beckmancoulter.com; Appendix 1) and assessed antimicrobial susceptibility patterns of *Chromobacterium* isolates (Appendix 1 Table).

We performed WGS on the 3 environmental and 2 clinical isolates (Appendix 1). For comparative genomic analysis, we used additional 16 genome sequences of *Chromobacterium* spp. from wastewater treatment plants in Tokyo and 52 publicly available genome sequences of *Chromobacterium* spp. from the NCBI Assembly database (https://www.ncbi.nlm.nih.gov/assembly) (Figure 1; Appendix 1; Appendix 2 Table 1, https://wwwnc.cdc.gov/EID/article/26/9/19-0670-App2.xlsx). We identified 19 strains of *C. haemolyticum* with 252,974 single-nucleotide variants by core-genome phylogenetic analysis (Figure 1; Appendix 2 Table 2). Metagenomic analysis of a river water sample collected from the site of the patient’s near-drowning revealed that the relative abundance of *Chromobacterium* is 0.07% (Figure 2). We deposited the complete genomic sequence of *C. haemolyticum* CH06-BL in GenBank (accession no. AP019312).

**Conclusions**

This severe case of drowning-associated pneumonia and bacteremia due to *C. haemolyticum* was successfully treated with appropriate antimicrobial therapy. Previously, 5 clinical cases of *C. haemolyticum* infections had been reported, including sputum colonization, necrotizing fasciitis with bacteremia, proctocolitis, pneumonia, and pediatric bacteremia (2,4,7–9). All patients, including the patient we report, survived after antimicrobial treatment. Intravenous antimicrobial therapy, such as meropenem or fluoroquinolone, is recommended for *C. haemolyticum* infections (7,9). The role of prolonged therapy for *C. haemolyticum* infections remains unclear, but in *C. violaceum* infections, an oral agent such as trimethoprim-sulfamethoxazole, tetracycline, or fluoroquinolone for 2–3 months can be used to prevent relapse (6).

As seen in the case we report, identification of *Chromobacterium* species is challenging. *C. violaceum* can produce a violet pigment (violacein) in most strains, and nonpigmented strains rarely have been
C. haemolyticum does not produce violacein and is characterized by strong hemolytic activity on sheep blood agar (2,4). Only C. violaceum is currently available in the genus Chromobacterium on the mass spectrometry database of species identification. Differentiation between C. haemolyticum and C. violaceum is crucial because C. haemolyticum has greater resistance to antimicrobial drugs, such as β-lactams (2,7). Although C. aquaticum is a nonpigmented, β-hemolytic strain phenotypically similar to C. haemolyticum has greater resistance to antimicrobial drugs, such as β-lactams (2,7). Although C. aquaticum is a nonpigmented, β-hemolytic strain phenotypically similar to C. haemolyticum, 16S rRNA sequencing might not determine either C. haemolyticum or C. aquaticum because of artificial separation of both species (4). Thus, WGS is a useful tool for accurate identification of Chromobacterium species to avoid misidentification of C. haemolyticum (1-5).

C. haemolyticum CH06-BL and other clinical and environmental isolates in this study possessed bla_{CRH-1} in the chromosome (Appendix 2 Table 1), but we did not identify mobile elements in the surrounding area. In a previous study, a class A β-lactamase, CRH-1 from C. haemolyticum was closely related to Klebsiella pneumoniae carbapenemase 2 (11). As seen in acquired resistance among other gram-negative bacilli, aquatic environments can be a reservoir (11,12).

The etiology of infections caused by Chromobacterium has not been fully elucidated. Of note, Chromobacterium accounted for only a small portion of the bacteria found in our metagenomics analysis of the river water, but this organism was isolated from the patient and was involved in human infection, despite presence of other potential pathogens in the river, such as Pseudomonas, Aeromonas, Legionella, that can cause pneumonia associated with drowning (Figure 2) (13). Our study isolates also had type III secretion system (T3SS) encoded by Chromobacterium pathogenicity island 1 and 1a (Cpi-1/-1a) (Appendix 1 Figure 2), which is known as a major virulence factor in C. violaceum (14). These results highlight the need for further research on antimicrobial resistance and virulence in Chromobacterium spp.

C. violaceum is widely distributed in natural aquatic environments and can be observed in water and soil sources, especially in tropical and subtropical areas (6). C. haemolyticum strains with genetic heterogeneity have been detected from lake water in a tropical region (15), but the bacterium’s habitat in temperate regions remains unknown. Our comparative genomic analysis revealed that clinical and environmental isolates of C. haemolyticum were discordant (27,867–29,491 single-nucleotide variants), although there was no standard definition for its clonality. Only 2 reports of cases with C. haemolyticum infections in temperate regions of Japan have been published (7,9). One study reported necrotizing fasciitis associated with exposure to river water after injury. The other described pneumonia caused by accidental aspiration of runoff water after a fall in a ditch and identification of the pathogen in the water and discordant results with clinical isolates by pulsed-field gel electrophoresis. However, detailed environmental investigations of the rivers as a source of the pathogen were not conducted in either article.

In summary, our genomic and environmental study demonstrates that C. haemolyticum in a local river, a natural habitat of this pathogen in Japan, caused...
Chromobacterium haemolyticum

Pneumonia, Japan

Clinicians should remain aware that river water in temperate regions can be a source of *C. haemolyticum* infection.

**Acknowledgments**

We thank David J. Weber for his careful review of the manuscript.

This work was supported in part by a grant for the Research on Emerging and Re-emerging Infectious Diseases and Immunization (grant no. H30 Shinkogyosei-Ippan-002) from the Ministry of Health, Labour and Welfare, Japan, and a grant from the Research Program on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development (grant nos. JP18fk0108048 and JP18fk0108019).

**About the Author**

Dr. Kanamori is an infectious disease physician at Tohoku University Hospital, Sendai, Japan. His primary research interests are antimicrobial resistance, environmental hygiene, and healthcare epidemiology.

**References**


Address for correspondence: Hajime Kanamori; Department of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan; email: kanamori@med.tohoku.ac.jp
Chromobacterium haemolyticum
Pneumonia Associated with Near-Drowning and River Water, Japan

Appendix 1

Methods

Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing of clinical and environmental isolates of Chromobacterium haemolyticum was performed by using a MicroScan WalkAway 96 plus (Beckman Coulter, https://www.beckmancoulter.com). Antimicrobial agents tested were as follows: ampicillin/sulbactam, piperacillin, piperacillin/tazobactam, ceftazidime, cefepime, cefozopran, cefoperazone/sulbactam, imipenem, meropenem, amikacin, gentamycin, tobramycin, minocycline, levofloxacin, ciprofloxacin, fosfomycin, aztreonam, chloramphenicol, and trimethoprim-sulfamethoxazole. The breakpoints for each antimicrobial drug were interpreted according to the 2016 Clinical and Laboratory Standards Institute guidelines (CLSI M100-S26; https://www.clsi.org).

Whole-Genome Sequencing

The genomic DNA library of all Chromobacterium spp. were constructed by using QIAseq FX DNA Library Kit (Qiagen, https://www.qiagen.com) according to the manufacturer’s instructions, then by paired-end sequencing using an Illumina NextSeq 500 platform with a 300-
cycle NextSeq 500 reagent kit v2 (Illumina, https://www.illumina.com). The metagenomic samples were sequenced by single-end sequencing by using 150-cycle NextSeq 500 Reagent Kit v2 (Illumina). The complete genome sequence of the strain was determined by using a PacBio Sequel (Pacific BioSciences, https://www.pacb.com) sequencer with Sequel SMRT Cell 1M v2 (four/tray) and Sequel sequencing kit v2.1 (Pacific BioSciences) for long-read sequencing (insert size, ≈10 kb). High quality genomic DNA was used to prepare a SMRTbell library by using a SMRTbell template prep kit 2.0 (Pacific Biosciences).

**de novo Assembly and Annotation**

The draft genome contigs were assembled by using A5-Miseq software version 20140604 with Illumina short reads (1). The circular genome sequence was constructed by using Canu version 1.4 (2), minimap version 0.2-r124 (3), racon version 1.1.0 (4), and Circlator version 1.5.3 (5) with long read data. Error correction of circular sequence was performed by using Pilon version 1.18 with short reads (6). Annotation was performed in DFAST version 1.0.8 (7) and NCBI-BLASTP/BLASTX against deposited Chromobacterium complete genome sequences.

**in silico Genomic and Metagenomic Analysis**

For comparative genomic analysis, we downloaded 52 publicly available genome sequences of Chromobacterium spp. from NCBI Assembly database (https://www.ncbi.nlm.nih.gov/assembly) (Appendix 1 Table). The species prediction was performed by using average nucleotide identity (ANI) with FastANI program version 1.1 (8), rpoB phylogenetic analysis with FastTree2 (9), and 16S rRNA gene identity search by using BLASTN (10) with 16S rRNA reference sequences of 12 Chromobacterium strains. The simulated 150 mer paired-end short reads were generated from the available genomic sequences by using SimSeq software (11). All short read data was mapped by using bwa-MEM program
against the *C. haemolyticum* CH06-BL complete genome sequence (accession no. AP019312) as a reference and single nucleotide variation (SNV) sites were extracted by using VarScan v2.3.4 (13). The repeat regions of CH06-BL genomic sequences were predicted by using NUCmer (14) and prophage regions were predicted by using PHASTER (15); SNVs on these regions were excluded. An SNV phylogenetic tree was constructed by the approximate maximum-likelihood method by using FastTree 2 (9), and visualized by using Figtree version 1.4.3 (http://tree.bio.ed.ac.uk/software/figtree).

To characterize the genomic features of *C. haemolyticum* CH06-BL, we performed a BLAST atlas analysis by using GView (16) and GView Server (https://server.gview.ca). We confirmed the organism classification of metagenomic sequences by using Centrifuge version 1.0.4 (17) with custom database that was built from nt database and RefSeq database of genomic sequences of bacteria, archaea, viruses, and humans.

**References**


**Appendix 1 Table.** Antimicrobial susceptibility patterns of clinical and environmental isolates of *Chromobacterium haemolyticum* associated with near-drowning and river water, Japan*

<table>
<thead>
<tr>
<th>Antimicrobial drug</th>
<th>Patient samples</th>
<th>Environmental samples</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CH06-SPT</td>
<td>CH06-BL</td>
<td>CH08-RW1</td>
<td>CH08-RW2</td>
<td>CH08-RW3</td>
</tr>
<tr>
<td>Ampicillin/sulbactam</td>
<td>&gt;32/16</td>
<td>&gt;32/16</td>
<td>&gt;32/16</td>
<td>&gt;32/16</td>
<td>&gt;32/16</td>
</tr>
<tr>
<td>Piperacillin</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>≤4</td>
<td>8</td>
<td>16</td>
<td>≤4</td>
<td>≤4</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>≤1</td>
<td>≤1</td>
<td>2</td>
<td>≤1</td>
<td>≤1</td>
</tr>
<tr>
<td>Cefepime</td>
<td>2</td>
<td>4</td>
<td>8</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Cefozopran</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Cefoperazone/sulbactam</td>
<td>≤8/4</td>
<td>32/16</td>
<td>&gt;32/16</td>
<td>≤8/4</td>
<td>≤8/4</td>
</tr>
<tr>
<td>Imipenem</td>
<td>4</td>
<td>&gt;8</td>
<td>&gt;8</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Meropenem</td>
<td>≤0.5</td>
<td>2</td>
<td>4</td>
<td>≤0.5</td>
<td>≤0.5</td>
</tr>
<tr>
<td>Amikacin</td>
<td>&gt;32</td>
<td>&gt;32</td>
<td>&gt;32</td>
<td>&gt;32</td>
<td>&gt;32</td>
</tr>
<tr>
<td>Gentamycin</td>
<td>&gt;8</td>
<td>&gt;8</td>
<td>&gt;8</td>
<td>&gt;8</td>
<td>&gt;8</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>&gt;8</td>
<td>&gt;8</td>
<td>&gt;8</td>
<td>&gt;8</td>
<td>&gt;8</td>
</tr>
<tr>
<td>Minocycline</td>
<td>≤1</td>
<td>≤1</td>
<td>4</td>
<td>≤1</td>
<td>4</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>≤0.5</td>
<td>≤0.5</td>
<td>≤0.5</td>
<td>≤0.5</td>
<td>≤0.5</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>≤0.25</td>
<td>≤0.25</td>
<td>≤0.25</td>
<td>≤0.25</td>
<td>≤0.25</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>&gt;16</td>
<td>&gt;16</td>
<td>&gt;16</td>
<td>&gt;16</td>
<td>&gt;16</td>
</tr>
<tr>
<td>Aztreonam</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>≤8</td>
<td>≤8</td>
<td>≤8</td>
<td>≤8</td>
<td>≤8</td>
</tr>
<tr>
<td>Trimethoprim-sulfamethoxazole</td>
<td>≤1/19</td>
<td>≤1/19</td>
<td>≤1/19</td>
<td>≤1/19</td>
<td>≤1/19</td>
</tr>
</tbody>
</table>

*Patient samples were collected from sputum and blood; environmental samples were collected from the river at the site of the patient’s near-drowning.
Appendix Figure 1. Heatmap of 16S rRNA of *Chromobacterium haemolyticum* in a case of pneumonia associated with near-drowning in river water, Japan. In total, 252,974 SNV sites were detected in core genome region among 19 strains. The phylogenetic analysis with SNV data was constructed by maximum likelihood method. Two clinical isolates (CH06-BL and CH06-SPT) and 3 environmental isolates (CH08-RW1, CH08-RW2, and CH08-RW3) of *C. haemolyticum* in this study were discordant (27,867–29,491 SNVs). Scale bar indicates nucleotide substitutions per site. SNV, single nucleotide variation.
Appendix Figure 2. Comparative genomic analysis among 19 strains of *Chromobacterium haemolyticum* in a case of pneumonia associated with near-drowning in river water, Japan. A complete chromosomal sequence of CH06-BL was determined by *de novo* assembly with short- and long-read data, followed by comparison using BLASTatlas analysis between strain CH06-BL and 18 *C. haemolyticum* strains. High homology (>80% nucleotide identity) regions against CH06-BL chromosome are displayed in each sample slot. Outer slot indicates genomic feature in CH06-BL chromosome; 4 genomic regions are conserved in clinical isolates from blood (yellow labels on outer slot). T3SS, type III secretion system; T5SS, type V secretion system.